Effects of safflower seed extract on arterial stiffness by Suzuki, Katsuya et al.
© 2010 Suzuki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2010:6 1007–1014
Vascular Health and Risk Management Dovepress




open access to scientific and medical research
Open Access Full Text Article
DOI:10.2147/VHRM.S13998








1Research institute for Health 
Fundamentals, Ajinomoto co., inc., 
Kawasaki; 2Samoncho clinic, Tokyo; 
3Shinanozaka clinic, Tokyo; 4Tokyo 
Medical University Hachioji Medical 
center, Tokyo, Japan
correspondence: Katsuya Suzuki
Research institute for Health 
Fundamentals, Ajinomoto co., inc. 1-1, 
Suzuki-cho, Kawasaki-ku, Kawasaki 
210-8681, Japan
Tel +81 44 210 5767
Fax +81 44 211 7609
email katsuya_suzuki@ajinomoto.com
Abstract: Safflower seed extract (SSE) contains characteristic polyphenols and serotonin 
derivatives (N-(p-coumaroyl) serotonin and N-feruloylserotonin), which are reported to inhibit 
oxidation of low-density lipoprotein (LDL), formation of atherosclerotic plaques, and improve 
arterial stiffness as assessed by pulse wave analysis in animal models. The effects of long-term 
supplementation with SSE on arterial stiffness in human subjects were evaluated. This double-
blind, placebo-controlled study was conducted in 77 males (35–65 years) and 15 postmeno-
pausal females (55–65 years) with high-normal blood pressure or mild hypertension who were 
not undergoing treatment. Subjects received SSE (70 mg/day as serotonin derivatives) or 
placebo for 12 weeks, and pulse wave measurements, ie, second derivative of photoplethys-
mogram (SDPTG), augmentation index, and brachial-ankle pulse wave velocity (baPWV) 
were conducted at baseline, and at weeks 4, 8, and 12. Vascular age estimated by SDPTG aging 
index improved in the SSE-supplemented group when compared with the placebo group at 
four (P = 0.0368) and 12 weeks (P = 0.0927). The trend of augmentation index reduction 
(P = 0.072 versus baseline) was observed in the SSE-supplemented group, but reduction of 
baPWV by SSE supplementation was not observed. The SSE-supplemented group also showed 
a trend towards a lower malondialdehyde-modified-LDL autoantibody titer at 12 weeks from 
baseline. These results suggest long-term ingestion of SSE in humans could help to improve 
arterial stiffness.
Keywords: safflower, serotonin derivatives, antioxidants, augmentation index, pulse wave 
velocity
Introduction
In Korea and other Asian countries, safflower (Carthamus tinctorius L.) seeds have 
been used as a traditional food or herbal medicine for the treatment of rheumatism 
and osteoporotic fractures.1,2 Among the polyphenols, two major serotonin derivatives, 
N-(p-coumaroyl) serotonin (CS) and N-feruloylserotonin (FS), have been identified 
as the characteristic components of defatted safflower seed extract (SSE).3–5 Serotonin 
derivatives have been shown to have potent antioxidant property,4,5 antitumor activity,1,6 
fibroblast proliferation stimulating activity,7 and protective effects against postischemic 
myocardial dysfunction.8 SSE, as well as serotonin derivatives, have been reported to 
have the ability to reduce atherosclerotic lesions in apolipoprotein E-deficient mice 
and in Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbits.5,9 Katsuda et al 
reported that SSE or serotonin derivatives reduced pulse wave velocity (a clinical 
parameter of noninvasive arterial stiffness) and ameliorated the pressure-strain elastic 





Parameters of arterial stiffness are associated with aging 
and increase the relative risk of atherosclerosis. Noninvasive 
pulse wave analysis methods, such as pulse wave velocity, 
augmentation index, and second derivative of the fingertip 
photoplethysmogram (SDPTG) have been developed to 
measure arterial stiffness. These methods have been postu-
lated to predict cardiovascular events.10–17 Several clinical 
studies have reported the use of drugs for the treatment of 
arterial stiffness. However, there are few reports on the use 
of functional food ingredients for this purpose. In a human 
pilot study, SSE supplementation was found to have a favor-
able effect on brachial-ankle pulse wave velocity (baPWV) 
in individuals with relatively high blood pressure (BP) or 
with a relatively high baPWV .18 Therefore, we investigated 
the effects of SSE on arterial stiffness in males and post-
menopausal females with high–normal BP or mild 
  hypertension. The endpoints were baPWV, augmentation 
index at the radial artery, and SDPTG.
Material and methods
This study was conducted according to the guidelines laid 
down in the Declaration of Helsinki, and all procedures 
involving human subjects were approved by the Clinical 
Trial Ethics Committee of the Shinanozaka Clinic, Tokyo, 
Japan. Written informed consent was obtained from all 
subjects.
Study protocol and subjects
This 12-week, double-blind, placebo-controlled study was 
conducted in 77 males (35–65 years) and 15 postmenopausal 
females (55–65 years) with high-normal BP or mild hyper-
tension. Before the main clinical examination, two prior 
measurements were carried out in enrolled subjects according 
to the following inclusion criteria: baPWV . 1250 cm/sec 
and rate of baPWV change between the two prior measure-
ments being ,7%. Subjects with a history or presence of 
cardiovascular disease, on medication for hypertension, 
hyperlipidemia, or diabetes mellitus, or medication for 
inflammatory disease, such as arthritis, dermatitis, and hepa-
titis, were excluded from the study. Subjects received three 
capsules of SSE (11.7 mg of serotonin derivatives [CS + FS] 
per capsule) or placebo (180 mg of lactose per capsule) twice 
a day for 12 weeks (total daily serotonin derivative intake 
70 mg/day). Measurements of pulse wave analysis at 
  baseline, and at weeks 4, 8 and 12, and blood sampling at 
weeks 0 and 12 were conducted in the morning after an 
overnight fast. Measurements were conducted twice and 
averaged to provide a daily mean value. During the treatment 
period, subjects were advised not to take medicines,   antioxidant 
supplements, polyunsaturated fatty acids, and food for spe-
cific lowering of high BP.
Preparation of SSe
Safflower seeds were provided by ADRI Limited (Sofia, 
Bulgaria). They were defatted by compression and 
extracted with 50% (v/v) ethanol. Extracted solutions were 
filtered and concentrated in vacuo. Water was added to the 
concentrated solution; this was kept overnight at room tem-
perature. The precipitate was mixed with the eluted super-
natant, which was loaded onto the adsorption column. The 
precipitate was then eluted using 50% (v/v) ethanol. After 
concentration in vacuo, the samples were freeze-dried. The 
obtained solid was crushed and filtered. Macronutrient and 
serotonin derivative compositions of the SSE are shown in 
Table 1. The SSE powder was filled in hard gelatin capsules 
and administered as an experimental dietary supplement.
Measurement procedures
BP and baPWV were measured simultaneously using an 
automated device, ie, pulse wave velocity/ABI   (BP-203RPE II; 
Omron Colin, Tokyo, Japan). The detailed methodology for 
measuring baPWV has been described elsewhere.18 In brief, 
four pneumatic pressure cuffs, two electrocardiographic 
electrodes, and a microphone for detecting heart sounds were 
attached to both the arms and ankles, both wrists, and on the 
left edge of the sternum to record the volume waveform for 
the brachial and ankle arteries. baPWV was automatically 
calculated as the length of an arterial segment between the 
brachium and ankle, which was automatically calculated 
from body height divided by transit time of the pulse wave. 
The mean of the left- and right-sided measurements of 
baPWV and BP were calculated to obtain a daily value. The 
method was validated in a previous report, and the inter- and 
intraobserver coefficients of variation were 8.4% and 10.0%, 
respectively.19
Table 1 Composition of safflower seed extract
SSE
energy (kJ/100 g) 1703.7
Protein (g/100 g) 19.1
Fat (g/100 g) 6.2
carbohydrate (g/100 g) 68.0
Ash (g/100 g) 3.0
Dietary fiber (g/100 g) 1.3
  cS (mg/g) 34.9
  FS (mg/g) 49.3
Abbreviations:  cS,  N-(p-coumaroyl)  serotonin;  FS,  N-feruloylserotonin;  SSe, 




Effects of safflower seed extract on arterial stiffness
Radial augmentation index was measured and calculated 
from the pulse wave using a semiautomatic pulse wave ana-
lyzer (HEM-9000 AI; Omron Colin). In brief, the arterial 
pulse wave was noninvasively obtained from the left radial 
artery by tonometric tracing. The 8 mm wide tonometric 
sensor comprised 40 arrayed microtransducers. The most 
appropriate microtransducer was automatically selected for 
optimal measurement. The hold-down pressure of the sensor 
head was automatically adjusted for each subject. Pulse 
waves were measured for 30 sec and digitized at 500 Hz. 
Radial augmentation index was calculated as the ratio of the 
late systolic pressure to pulse pressure, ie:
Late systolic BP - diastolic BP/(systolic BP  
  - diastolic BP) × 100 (%)
Radial augmentation index was automatically calculated 
using a fourth-order differential equation for a radial arterial 
waveform (HEM-9000 AI). Measurement was carried out 
with subjects in the sitting position. The coefficients of 
variation for intra- and interobserver measurements for the 
radial aging index using this device were 4.3% and 2.5%, 
respectively.20
SDPTG was measured by fingertip   photoplethysmography 
(SDP-100; Fukuda Denshi, Tokyo, Japan). The sensor was 
placed on the cuticle of the second digit of the left hand. 
During the measurement, subjects rested on a bed in a quiet 
room. The SDPTG consists of five specific waves, ie, a, b, c, 
and d systolic waves, and an e wave that is diastolic. Ratios 
for the following parameters were obtained: b/a, d/a, and 
SDPTG aging index (SDPTG-AI; (b - c - d - e)/a). Vascular 
age was calculated for males as 43.5 × SDPTG-AI + 65.9 years 
and for females as 41.7 × SDPTG-AI + 61.8 years.15 Repro-
ducibility of the SDPTG has been previously reported, with 
an intraobserver repeatability of 8%.21
Biochemical parameters
Plasma glucose and serum lipids, ie, total cholesterol, low-
density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, and triglycerides, were measured at SRL 
Inc. (Tokyo, Japan) using its standard laboratory protocols.
Oxidative stress status
Serum autoantibody titers to malondialdehyde-modified LDL 
(anti-MDA-LDL) were measured by enzyme-linked immuno-
sorbent assay (ELISA).18 Oxidized LDLs in serum were mea-
sured as 4E6 monoclonal antibody-reactive substances using 
an oxidized LDL competitive ELISA kit (Mercodia, Uppsala, 
Sweden). The parameters were measured at SRL Inc.
Proinflammatory markers
The serum-soluble form of vascular cell adhesion molecule-1 
(sVCAM-1), the soluble form of intercellular adhesion 
molecule-1 (sICAM-1), and monocyte chemotactic protein-1 
(MCP-1) were measured at SRL Inc. using Quantikine 
Immunoassay kits (R&D Systems, Minneapolis, MN).
Statistical analysis
Results are represented as mean ± standard deviation unless 
otherwise stated. All data analyses were conducted using the 
Statistical Software for Social Sciences (15.0.1 (SPSS, Inc., 
Chicago, IL). Changes from baseline between the groups 
were compared using analysis of covariance, adjusting for 
each baseline result. Comparison with baseline (0 week) in 
the same group was conducted by paired t-test.
Results
Subject characteristics
Clinical characteristics of subjects included in this study are 
presented in Table 2. Before administration of the test 
  material, baPWV in the placebo group was significantly 
higher than that in the SSE-supplemented group (P = 0.0231). 
Other factors were not significantly different between the 
two groups. None of the subjects had serious conditions, such 
as pulmonary or renal disease.
During the study, three subjects in the SSE-supplemented 
group were excluded from analysis (two due to failure to 






Male 39 38 1.0000
Female 7 8
Age (y) 51.6 ± 7.2 50.6 ± 8.1 0.5055
Body height (cm) 168.22 ± 7.11 168.98 ± 7.22 0.6108
Body weight (kg) 67.49 ± 8.81 69.03 ± 11.62 0.4760
Body mass index (%) 23.81 ± 2.40 24.12 ± 3.43 0.6169
baPWV (cm/sec) 1449.2 ± 125.0 1390.5 ± 118.5 0.0231
Brachial blood pressure (mmHg)
SBP 131.7 ± 13.3 127.0 ± 9.8 0.0588
DBP 83.4 ± 8.3 81.5 ± 7.5 0.2478
b/a -0.545 ± 0.113 -0.563 ± 0.155 0.5139
d/a -0.362 ± 0.091 -0.330 ± 0.104 0.1219
SDPTg-Ai -0.254 ± 0.264 -0.318 ± 0.326 0.3045
Vascular age (y) 54.5 ± 11.2 52.1 ± 13.8 0.3578
Aix (%) 83.7 ± 12.8 81.1 ± 12.6 0.3446
Notes:  Results  are  mean  ±  standard  deviation.  Probability  value  refers  to  the 
difference between the treatment groups.
Abbreviations: baPWV, brachial-ankle pulse wave velocity; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; SDPTG-AI, second derivative of a finger 





attend the study, and one due to development of   hyperuricemia). 
Statistical analysis of the SSE-supplemented group was 
conducted in 44 and 43 subjects after eight and 12 weeks of 
SSE supplementation, respectively.
effects of SSe on BP and arterial stiffness
Table 3 shows values and changes in least-squares mean of 
BP and arterial stiffness parameters from baseline, after 
ingestion of test meals at weeks 4, 8, and 12. At four weeks, 
the SSE-supplemented group showed lower SDPTG-AI and 
b/a (P = 0.0620 and 0.0507, respectively) than the placebo 
group. Vascular age was significantly lower in the SSE-
supplemented group at four weeks (P = 0.0368) and remained 
significantly lower at 12 weeks (P = 0.0927) than in the 
placebo group. There were no significant differences in 
systolic BP, diastolic BP, baPWV , and augmentation index 
between the two groups.
Blood analysis
Biochemical parameters, oxidative stress, and proinflamma-
tory markers in blood at baseline and 12 weeks after ingestion 
of test meals are presented in Table 4. Significant variations 
in LDL cholesterol at 12 weeks from baseline were observed 
in the SSE-supplemented group. There was no significant 
change from baseline for other biochemical parameters in 
either group at 12 weeks. No significant changes in oxidative 
Table 3 effects of SSe supplementation on arterial stiffness and blood pressure
Week Measurement value  Least-squares mean change from baseline (95% CI)
Placebo group SSE group Placebo group SSE group P
Brachial blood pressure (mmHg)
SBP Baseline 131.7 ± 13.3 127.0 ± 9.8
4 130.9 ± 12.1 127.3 ± 8.7 0.00 (-2.12 to 2.12) 0.7391 
8 129.3 ± 12.0 126.7 ± 9.2 -1.74 (-3.92 to 0.44) -1.51 (-3.74 to 0.72) 0.8819 
12 129.8 ± 11.3 126.2 ± 9.1 -1.28 (-3.27 to 0.72) -2.09 (-4.16 to -0.02) 0.5781 
DBP Baseline 83.4 ± 8.3 81.5 ± 7.5
4 83.6 ± 8.8 81.1 ± 7.1 0.39 (-1.04 to 1.82) -0.49 (-1.92 to 0.94) 0.3880 
8 83.0 ± 9.3 81.1 ± 7.8 -0.27 (-1.88 to 1.34) -0.75 (-2.39 to 0.90) 0.6827 
12 82.7 ± 7.8 80.1 ± 8.0 -0.48 (-2.02 to 1.05) -1.75 (-3.34 to -0.17) 0.2570 
baPWV (cm/s) Baseline 1449.2 ± 125.0 1390.5 ± 118.5
4 1468.2 ± 151.8 1420.0 ± 118.7 23.36 (-2.98 to 49.71) 25.21 (-1.14 to 51.56) 0.9231 
8 1455.0 ± 129.4 1408.9 ± 126.5 10.76 (-13.49 to 35.01) 9.43 (-15.38 to 34.24) 0.9402 
12 1440.0 ± 116.8 1389.6 ± 110.2 -1.20 (-24.08 to 21.67) -14.65 (-38.33 to 9.03) 0.4246 
b/a Baseline -0.545 ± 0.113 -0.563 ± 0.155
4 -0.526 ± 0.114 -0.575 ± 0.153 0.021 (-0.005 to 0.046) -0.016 (-0.041 to 0.010) 0.0507 
8 -0.541 ± 0.111 -0.571 ± 0.133 0.006 (-0.018 to 0.030) -0.017 (-0.041 to 0.008) 0.1877 
12 -0.534 ± 0.127 -0.572 ± 0.145 0.011 (-0.013 to 0.036) -0.018 (-0.044 to 0.008) 0.1049 
d/a Baseline -0.362 ± 0.091 -0.330 ± 0.104
4 -0.379 ± 0.092 -0.341 ± 0.103 -0.022 (-0.041 to -0.002) -0.005 (-0.025 to 0.015) 0.2413 
8 -0.362 ± 0.095 -0.334 ± 0.108 -0.004 (-0.027 to 0.019) 0.004 (-0.019 to 0.028) 0.6163 
12 -0.362 ± 0.108 -0.320 ± 0.126 -0.003 (-0.028 to 0.023) 0.018 (-0.009 to 0.045) 0.2756 
SDPTg-Ai Baseline -0.2539 ± 0.2641 -0.3178 ± 0.3262
4 -0.1990 ± 0.2428 -0.3139 ± 0.3274 0.061 (-0.011 to 0.111) -0.006 (-0.057 to 0.044) 0.0620 
8 -0.2409 ± 0.2582 -0.3191 ± 0.3010 0.020 (-0.033 to 0.073) -0.022 (-0.077 to 0.032) 0.2740 
12 -0.2384 ± 0.2741 -0.3373 ± 0.3177 0.021 (0.024 to 0.076) -0.032 (-0.088 to 0.024) 0.1880 
Vascular age (y) Baseline 54.5 ± 11.2 52.1 ± 13.8
4 57.1 ± 10.1 52.0 ± 13.8 2.83 (0.59 to 5.06) -0.57 (-2.83 to 1.69) 0.0368 
8 55.5 ± 11.1 51.7 ± 12.4 1.24 (-1.13 to 3.61) -1.25 (-3.67 to 1.17) 0.1473 
12 55.4 ± 11.5 51.3 ± 13.5 1.05 (-1.24 to 3.34) -1.77 (-4.14 to 0.60) 0.0927 
Aix (%) Baseline 83.7 ± 12.8 81.1 ± 12.6
4 82.6 ± 13.6 80.5 ± 11.9 -0.89 (-2.91 to 1.14) -0.95 (-3.00 to 1.10) 0.9652 
  8 84.1 ± 13.1 80.4 ± 11.8 0.68 (-1.59 to 2.95) -1.62 (-3.94 to 0.71) 0.1646 
12 82.5 ± 12.7 79.6 ± 12.8 -1.03 (-3.08 to 1.02) -2.14 (-4.27 to -0.02) 0.4561 
Notes: Results are mean ± standard deviation. Probability value refers to the difference between the treatment groups.
Abbreviations:  SBP,  systolic  blood  pressure;  DBP,  diastolic  blood  pressure;  baPWV,  brachial-ankle  pulse  wave  velocity;  SDPTG-AI,  second  derivative  of  a  finger 




Effects of safflower seed extract on arterial stiffness
stress markers (oxidized LDL and anti-MDA-LDL) or 
  proinflammatory markers (sICAM-1, sVCAM-1, and 
MCP-1) were observed in either group. Anti-MDA-LDL in 
the SSE-supplemented group at 12 weeks tended to be lower 
than at baseline (P = 0.078 versus baseline, SSE group).
Discussion
The effect of SSE ingestion on arterial stiffness was investi-
gated in subjects with high–normal BP or mild hypertension 
in this placebo-controlled, double-blind study. In a pilot 
study, four weeks of SSE supplementation was found to exert 
a favorable effect on baPWV in individuals with relatively 
high BP, or with a relatively high baPWV .18 Therefore, in 
this study, to determine the effect of SSE on baPWV 
  precisely, we enrolled subjects on the basis of the two afore-
mentioned inclusion criteria, and a prolonged treatment 
period of 12 weeks of SSE supplementation did not have a 
significant effect on baPWV. The nature of pulse wave 
  velocity is significantly influenced by BP, and a pilot study 
suggested that SSE affects vascular function by reducing BP, 
which resulted in the reduction of baPWV . However, it is 
unclear whether reduction in BP was due to SSE supplemen-
tation, because the pilot study was an open-label, non- 
placebo-controlled study. In addition, baPWV seems to be 
primarily associated with structural distensibility in large 
arteries, and long-term treatment would be required to 
improve baPWV . Treatment with drugs (eg, angiotensin II 
receptor blockers, antidiabetic agents, and eicosapentaenoic 
acid) were continued for .six months in several clinical 
studies of baPWV .22–25 We suggest that a prolonged treatment 
period is required to reach definitive conclusions about the 
effect of SSE on baPWV .
SDPTG is one of the alternative methods for assessment 
of arterial stiffness, and this method can be used to estimate 
vascular age.16 It is noninvasive and easy for patients to 
undergo, and we consider that SDPTG is a good parameter 
of arterial stiffness. Some SDPTG quantifiers were found to 
be closely correlated with ascending aortic augmentation 
index, age, and other atherosclerotic risk factors.14–17 The 
SSE-supplemented group showed significant reduction in 
vascular age, as estimated by SDPTG-AI at four weeks, and 
showed a lower vascular age than that of the placebo group 
at 12 weeks. In addition, the effects of SSE were more 
prominent in a subgroup aged 40–59 years, although the base-
line characteristics of each subgroup are similar to those of 
all subjects (Tables 5 and 6). The age group is a putative core 
target of metabolic syndrome, and a remarkable change with 
age has been reported for SDPTG.26 Because measurement 
of SDPTG is performed in peripheral vessels, it may be 
affected more by the peripheral artery characteristics than 
by pulse wave velocity. Therefore, SSE might ameliorate 
peripheral arterial properties and be able to detect the effects 
of short-term treatment.
The a and b waves corresponded to the early systolic 
component and the d wave corresponded to the late systolic 
component of the SDPTG. Therefore, the b/a ratio is con-
sidered to be a marker of the distensibility of large arteries 
(which is little affected by the reflection wave), and the d/a 
ratio is closely related to late systolic pressure augmentation 
in the ascending aorta (and hence regarded as a marker of 
wave reflection intensity). Increase in the b/a ratio and 
decrease in the d/a ratio are associated with aging. The SSE-
supplemented group showed a tendency towards a decreased 
b/a ratio (P = 0.0507 compared with the placebo group at 
Table 4 Results according to treatment in each group
Placebo SSE
0 w 12 w 0 w 12 w
Total cholesterol (mg/dL)   205.9 ± 29.7   202.9 ± 32.8   214.8 ± 28.8   209.6 ± 14.8
LDL cholesterol (mg/dL)   125.8 ± 28.3   122.2 ± 31.6   131.9 ± 27.0   124.2 ± 25.3*
HDL cholesterol (mg/dL)   54.8 ± 14.3   54.0 ± 12.5   57.7 ± 16.5   56.8 ± 15.3
Triglycerides (mg/dL)   119.6 ± 62.2   108.8 ± 65.6   114.9 ± 57.7   109.5 ± 74.1
glucose (mg/dL)   102.1 ± 10.0   102.8 ± 14.1   100.3 ± 8.9   101.4 ± 8.7
sicAM-1  (ng/mL)   207.3 ± 57.8   201.0 ± 57.8   184.8 ± 62.7   177.2 ± 60.3
sVcAM-1  (ng/mL)   586.7 ± 153.6   607.8 ± 162.6   548.0 ± 178.7   573.9 ± 137.4
McP-1  (pg/mL)   255.7 ± 69.5   251.1 ± 58.1   270.5 ± 72.3   256.9 ± 66.2
Oxidized LDL  (U/L)   73.2 ± 12.9   72.3 ± 14.8   74.8 ± 12.9   71.4 ± 11.9
Anti-MDA-LDL (AU) 150.52 ± 63.10 141.23 ± 61.24 175.70 ± 131.04 138.75 ± 61.82
Notes: Results are mean ± standard deviation. Probability value refers to the comparison of the value at baseline (0 W) (*P , 0.05), as revealed by paired t-test.
Abbreviations: sicAM-1, soluble intercellular adhesion molecule-1; sVcAM-1, soluble vascular cell adhesion molecule-1; McP-1, monocyte chemotactic protein-1; anti 
MDA-LDL, autoantibody titers to malondialdehyde-modified LDL; AU, arbitrary unit; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 





four weeks). This may indicate improvement in distensibility 
of the large arteries by SSE supplementation. Katsuda et al 
showed that the elasticity of large arteries improved in KHC 
rabbits after four weeks of SSE treatment,9 and the results 
of their study are consistent with those of our study with 
regard to the effect of SSE. However, the lack of effect of 
SSE on baPWV, mainly reflected in the large arteries, is 
considered to contradict the results of b/a, as described above. 
This discrepancy needs to be resolved in the future.
Although there was no difference between the placebo 
and SSE-supplemented groups with respect to augmentation 
index, there was a tendency towards a reduction in augmenta-
tion index in the SSE-supplemented group at 12 weeks 
(P = 0.072 compared with baseline). The augmentation index 
was obtained from the central arterial waveform as the ratio 
of augmentation pressure to total pulse pressure. The aug-
mentation index can also be obtained from the radial arterial 
waveform, and the radial augmentation index can provide 
information on vascular aging and arterial stiffness. Our 
findings of improvements in vascular age as estimated by 
SDPTG-AI and the augmentation index could suggest that 
supplementation with SSE decreases vascular aging and the 
risk of cardiovascular disease.
In a pilot study, Koyama et al used a daily serotonin 
derivative dose of 290 mg/day.18 However, in our study 
we used a daily serotonin derivative dose of 70 mg/day. The 
dose discrepancy between the studies could be due to the 
presence or absence of serotonin derivative glycosides as 
active compounds in SSE. We consider the effect of serotonin 
derivatives on arterial stiffness to be substantially dependent 
on aglycon type, because the bioavailability of serotonin 
derivative glycosides was found to be lesser than that of 
aglycons in rats.27 Therefore, we only analyzed the intake of 
serotonin derivative aglycons in this study.
Reactive oxygen species in the vessel wall have been 
considered to be one of the most important causes of vascular 
dysfunction. The oxidative modification of LDL has been 
shown to play a major role in the genesis of atherosclerosis. 
Antioxidative dietary components, such as polyphenols, have 
recently attracted considerable attention because they were 
found to be effective for the prevention of cardiovascular 
disease.28,29 SSE contains some serotonin derivatives, mainly 
CS and FS, which have been reported to act as potent free 
radical scavengers.4,5 Koyama et al showed that both intact 
and conjugated forms of CS and FS were detectable in the 
plasma of apolipoprotein E-deficient mice fed a diet contain-
ing SSE. Long-term supplementation of serotonin derivatives 
inhibited CuSO4-induced plasma lipid oxidation ex vivo and 
decreased the plasma titer of autoantibodies to oxidized LDL 
and plasma lipid peroxides in apolipoprotein E-deficient 
mice.5 Significant reductions in the levels of circulating 
oxidized LDL, anti-MDA-LDL, and urinary 8-isoprostane 
were observed after a four-week administration of SSE in a 
human pilot trial.18 In the present study, the anti-MDA-LDL 
titer in the SSE group was found to be lower than that in the 






Male 30 28 1.0000
Female 6 6
Age (years) 52.1 ± 4.4 51.0 ± 5.6 0.3437
Body height (cm) 168.23 ± 7.36 169.01 ± 7.54 0.6613
Body weight (kg) 66.79 ± 8.56 67.84 ± 10.61 0.6492
Body mass index (%) 23.56 ± 2.28 23.69 ± 2.98 0.8323
baPWV (cm/sec) 1451.6 ± 125.8 1386.0 ± 99.9 0.0187
Brachial blood pressure (mmHg)
SBP 133.1 ± 13.2 127.1 ± 10.5 0.0391
DBP 84.6 ± 7.6 82.9 ± 7.3 0.3501
b/a -0.543 ± 0.112 -0.556 ± 0.143 0.6527
d/a -0.368 ± 0.087 -0.347 ± 0.101 0.3378
SDPTg-Ai -0.251 ± 0.263 -0.292 ± 0.302 0.5470
Vascular age (y) 54.5 ± 11.0 53.1 ± 12.7 0.6348
Aix (%) 84.4 ± 13.5 82.5 ± 11.2 0.5306
Notes:  Results  are  mean  ±  standard  deviation.  Probability  value  refers  to  the 
difference between the treatment groups. 
Abbreviations: baPWV, brachial-ankle pulse wave velocity; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; SDPTG-AI, second derivative of a finger 
photoplethysmogram  aging  index;  AIx,  augmentation  index;  SSE,  safflower  seed 
extract.
Table 6 effects of SSe supplementation on vascular age in a subgroup aged 40–59 years





Placebo group SSE group P
Vascular age (y) baseline 54.45 ± 11.02 53.10 ± 12.73
4 w 57.72 ± 10.23 51.96 ± 13.60 3.39 (0.74 to 6.04) -1.53 (-4.30 to 1.23) 0.0126
8 w 57.65 ± 10.39 52.11 ± 12.15 3.25 (0.78 to 5.73) -1.97 (-4.60 to 0.65) 0.0052
12 w 56.56 ± 11.33 52.21 ± 12.43 2.11(-0.39 to 4.61) -2.14 (-4.84 to 0.55) 0.0241
Notes: Results are mean ± standard deviation. Probability value refers to the difference between the treatment groups.




Effects of safflower seed extract on arterial stiffness
placebo group, although reduction of oxidized LDL by SSE 
was not detected. These data suggest that SSE could inhibit 
oxidized LDL formation and oxidized LDL-mediated vas-
cular injury, and that this effect contributes to amelioration 
of arterial stiffness. Reduction in the level of LDL cholesterol 
at 12 weeks was also observed in the SSE group. However, 
the hypocholesterolemic effect of SSE or serotonin deriva-
tives have not been confirmed reproducibly in animal and 
human studies.5,18 In addition, there is a possibility that other 
lipid-lowering diets influenced the results. However, we 
could not evaluate this possibility because we were not able 
to determine whether or not the subjects took a particular 
diet that lowers lipids. The association of hypocholester-
olemic activity with the effect of SSE on arterial stiffness 
needs to be carefully assessed in the future.
Takimoto et al reported that CS and FS show direct vas-
cular relaxation effects in the thoracic aorta and femoral artery 
of rats.29,30 Piga et al reported that CS and FS exert an inhibi-
tory effect on short-term high glucose-induced upregulation 
of mRNA and proteins of adhesion and migration factors, 
and the consequent adhesion and migration of monocytes to 
endothelial cells.31 These effects may also contribute to 
amelioration of arterial stiffness by SSE supplementation.
This study had some limitations. First, we could not 
analyze smoking status in our subjects, which is an important 
avoidable risk factor for arterial stiffness, although subjects 
were advised not to smoke on the day of pulse wave analysis. 
Second, baPWV was significantly higher and systolic BP 
was marginally higher at baseline in the placebo group in 
this study. We do not know the exact reason for this. Third, 
we enrolled males aged 35–65 years and postmenopausal 
females aged 55–56 years in this study, and age and gender 
are the first variables that limit the application of such 
  techniques.32 The consideration of the effects of SSE is lim-
ited to the group described above.
Although arterial stiffness parameters have been postulated 
to predict cardiovascular events, there are few interventional 
studies on the effect of functional food ingredients. We believe 
that this study may provide information regarding the clinical 
effects of functional food ingredients on these parameters. SSE 
supplementation for 12 weeks did not have any severe adverse 
health effects. In addition, we showed that high-dose SSE 
supplementation (210 mg/day as serotonin derivative aglycons) 
for four weeks did not have severe adverse effects.33 These 
findings suggest that SSE may be safe for daily use as a dietary 
supplement over a long time period. In conclusion, this study 
suggests that SSE   ameliorates arterial stiffness and therefore 
may have the potential to decrease cardiovascular risk.
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